Browse SPHK2

Summary
SymbolSPHK2
Namesphingosine kinase 2
Aliases SK-2; SPK 2; SPK-2; sphingosine kinase type 2
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cytoplasm. Membrane.; SUBCELLULAR LOCATION: Isoform 2: Lysosome membrane.
Domain PF00781 Diacylglycerol kinase catalytic domain
Function

Catalyzes the phosphorylation of sphingosine to form sphingosine 1-phosphate (SPP), a lipid mediator with both intra- and extracellular functions. Also acts on D-erythro-dihydrosphingosine, D-erythro-sphingosine and L-threo-dihydrosphingosine. Binds phosphoinositides.

> Gene Ontology
 
Biological Process GO:0003376 sphingosine-1-phosphate signaling pathway
GO:0006066 alcohol metabolic process
GO:0006643 membrane lipid metabolic process
GO:0006644 phospholipid metabolic process
GO:0006665 sphingolipid metabolic process
GO:0006668 sphinganine-1-phosphate metabolic process
GO:0006669 sphinganine-1-phosphate biosynthetic process
GO:0006670 sphingosine metabolic process
GO:0007565 female pregnancy
GO:0008654 phospholipid biosynthetic process
GO:0019751 polyol metabolic process
GO:0030148 sphingolipid biosynthetic process
GO:0030258 lipid modification
GO:0034311 diol metabolic process
GO:0034312 diol biosynthetic process
GO:0044283 small molecule biosynthetic process
GO:0044706 multi-multicellular organism process
GO:0046165 alcohol biosynthetic process
GO:0046173 polyol biosynthetic process
GO:0046467 membrane lipid biosynthetic process
GO:0046512 sphingosine biosynthetic process
GO:0046519 sphingoid metabolic process
GO:0046520 sphingoid biosynthetic process
GO:0046834 lipid phosphorylation
GO:0090520 sphingolipid mediated signaling pathway
GO:1901615 organic hydroxy compound metabolic process
GO:1901617 organic hydroxy compound biosynthetic process
Molecular Function GO:0001727 lipid kinase activity
GO:0008481 sphinganine kinase activity
GO:0017016 Ras GTPase binding
GO:0017050 D-erythro-sphingosine kinase activity
GO:0031267 small GTPase binding
GO:0038036 sphingosine-1-phosphate receptor activity
GO:0045125 bioactive lipid receptor activity
GO:0051020 GTPase binding
Cellular Component GO:0005765 lysosomal membrane
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04020 Calcium signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04370 VEGF signaling pathway
hsa04666 Fc gamma R-mediated phagocytosis
hsa00600 Sphingolipid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1660661: Sphingolipid de novo biosynthesis
R-HSA-428157: Sphingolipid metabolism
Summary
SymbolSPHK2
Namesphingosine kinase 2
Aliases SK-2; SPK 2; SPK-2; sphingosine kinase type 2
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SPHK2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SPHK2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29277894Non-Small Cell Lung CarcinomaInhibit immunity; decrease the efficacy of immunotherapy; immunotherapy targetSphK2 expression predicts poor survival in NSCLC patients, and is associated with Gefitinib-resistance.
23373542Breast Carcinoma; Osteosarcoma; Pancreatic AdenocarcinomaPromote immunitythese findings revealed that PhotoImmunoNanoTherapy, utilizing the novel nontoxic theranostic agent ICG-CPSNP, can decrease tumor-associated inflammation and immature myeloid cells in a sphingosine kinase 2-dependent manner.
Summary
SymbolSPHK2
Namesphingosine kinase 2
Aliases SK-2; SPK 2; SPK-2; sphingosine kinase type 2
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SPHK2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSPHK2
Namesphingosine kinase 2
Aliases SK-2; SPK 2; SPK-2; sphingosine kinase type 2
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SPHK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141200.999
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0910.954
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.070.95
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4390.258
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.5210.798
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.340.9
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0220.933
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0150.985
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0380.972
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0130.99
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.0560.969
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1050.28
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SPHK2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSPHK2
Namesphingosine kinase 2
Aliases SK-2; SPK 2; SPK-2; sphingosine kinase type 2
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SPHK2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSPHK2
Namesphingosine kinase 2
Aliases SK-2; SPK 2; SPK-2; sphingosine kinase type 2
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SPHK2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SPHK2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSPHK2
Namesphingosine kinase 2
Aliases SK-2; SPK 2; SPK-2; sphingosine kinase type 2
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SPHK2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSPHK2
Namesphingosine kinase 2
Aliases SK-2; SPK 2; SPK-2; sphingosine kinase type 2
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SPHK2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSPHK2
Namesphingosine kinase 2
Aliases SK-2; SPK 2; SPK-2; sphingosine kinase type 2
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SPHK2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSPHK2
Namesphingosine kinase 2
Aliases SK-2; SPK 2; SPK-2; sphingosine kinase type 2
Chromosomal Location19q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SPHK2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.